EFFECT OF TREATMENT OF METABOLIC ACIDOSIS IN CHRONIC KIDNEY DISEASE (CKD): A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/nnmhs.v9i7.1768Keywords:
Acid base balance, Bicarbonate sodium, Chronic kidney disease (CKD), Metabolic acidosisAbstract
Background: Plasma anions outweigh cations in metabolic acidosis. Metabolic acidosis may aggravate renal impairment. Sodium bicarbonate may help. Sodium bicarbonate in maintenance dialysis produces metabolic alkalosis. In chronic renal illness, sodium bicarbonate may worsen vascular calcifications.
Aim: This article examines the link between effect of treatment of metabolic acidosis in chronic kidney disease (CKD).
Methods: By evaluating the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 standards, this study demonstrated that it met all of the requirements. This enabled the researchers to ensure that the study was as up to date as feasible. Publications published between 2000 and 2023 were included in the search strategy, which included a variety of electronic reference databases (including Pubmed and SagePub). We did not consider review papers, duplicate publications, or half completed articles.
Result: In the PubMed database, the results of our search brought up 388 articles, whereas the results of our search on SagePub brought up 201 articles. The results of the search conducted for the last year of 2013 yielded a total of 48 articles for PubMed and 22 articles for SagePub. In the end, we compiled a total of 25 papers, 17 of which came from PubMed and eight of which came from SagePub. We included eight research that met the criteria.
Conclusion: The findings of the current investigation demonstrated that supplementation with alkali had a beneficial effect on preserving LBM and GFR in patients with CKD.
References
Melamed ML, Raphael KL. Metabolic Acidosis in CKD: A Review of Recent Findings. Kidney Med. 2021;3(2):267–77.
Karim Z, Attmane-Elakeb A, Bichara M. Renal handling of NH4+ in relation to the control of acid-base balance by the kidney. J Nephrol. 2002;15 Suppl 5:S128-34.
Batlle D, Chin-Theodorou J, Tucker BM. Metabolic Acidosis or Respiratory Alkalosis? Evaluation of a Low Plasma Bicarbonate Using the Urine Anion Gap. Am J kidney Dis Off J Natl Kidney Found. 2017 Sep;70(3):440–4.
Kraut JA, Kurtz I. Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment. Am J kidney Dis Off J Natl Kidney Found. 2005 Jun;45(6):978–93.
Nagami GT, Hamm LL. Regulation of Acid-Base Balance in Chronic Kidney Disease. Adv Chronic Kidney Dis. 2017 Sep;24(5):274–9.
Wesson DE, Buysse JM, Bushinsky DA. Mechanisms of Metabolic Acidosis-Induced Kidney Injury in Chronic Kidney Disease. J Am Soc Nephrol. 2020 Mar;31(3):469–82.
Kim HJ. Metabolic Acidosis in Chronic Kidney Disease: Pathogenesis, Clinical Consequences, and Treatment. Electrolyte Blood Press. 2021 Dec;19(2):29–37.
Chen W, Levy DS, Abramowitz MK. Acid Base Balance and Progression of Kidney Disease. Semin Nephrol. 2019 Jul;39(4):406–17.
Kim HJ, Ryu H, Kang E, Kang M, Han M, Song SH, et al. Metabolic Acidosis Is an Independent Risk Factor of Renal Progression in Korean Chronic Kidney Disease Patients: The KNOW-CKD Study Results. Front Med. 2021;8:707588.
Kraut JA, Madias NE. Metabolic Acidosis of CKD: An Update. Am J kidney Dis Off J Natl Kidney Found. 2016 Feb;67(2):307–17.
Raphael KL. Metabolic Acidosis in CKD: Core Curriculum 2019. Am J kidney Dis Off J Natl Kidney Found. 2019 Aug;74(2):263–75.
Mathur VS, Bushinsky DA, Inker L, Klaerner G, Li E, Parsell D, et al. Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2023 May;38(6):1448–58.
Mathur VS, Wesson DE, Tangri N, Li E, Bushinsky DA. Effects of veverimer on serum bicarbonate and physical function in women with chronic kidney disease and metabolic acidosis: a subgroup analysis from a randomised, controlled trial. BMC Nephrol. 2022 Feb;23(1):82.
Kittiskulnam P, Srijaruneruang S, Chulakadabba A, Thokanit NS, Praditpornsilpa K, Tungsanga K, et al. Impact of Serum Bicarbonate Levels on Muscle Mass and Kidney Function in Pre-Dialysis Chronic Kidney Disease Patients. Am J Nephrol. 2020;51(1):24–34.
Dubey AK, Sahoo J, Vairappan B, Haridasan S, Parameswaran S, Priyamvada PS. Correction of metabolic acidosis improves muscle mass and renal function in chronic kidney disease stages 3 and 4: a randomized controlled trial. Nephrol Dial Transplant. 2020;35(1):121–9.
Di Iorio BR, Bellasi A, Raphael KL, Santoro D, Aucella F, Garofano L, et al. Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study. J Nephrol. 2019 Dec;32(6):989– 1001.
Wesson DE, Mathur V, Tangri N, Stasiv Y, Parsell D, Li E, et al. Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial. Lancet (London, England). 2019 Apr;393(10179):1417–27.
Bellasi A, Di Micco L, Santoro D, Marzocco S, De Simone E, Cozzolino M, et al. Correction of metabolic acidosis improves insulin resistance in chronic kidney disease. BMC Nephrol. 2016 Oct;17(1):158.
Goraya N, Simoni J, Jo C-H, Wesson DE. Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate. Kidney Int. 2014;86(5):1031–8.
Adamczak M, Masajtis-Zagajewska A, Mazanowska O, Madziarska K, Stompór T, Więcek A. Diagnosis and Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease – Position Statement of the Working Group of the Polish Society of Nephrology. Kidney Blood Press Res [Internet] 2018 Jun 7;43(3):959–69. Available from: https://doi.org/10.1159/000490475
Adeva-Andany MM, Fernández-Fernández C, Mouriño-Bayolo D, Castro-Quintela E, Domínguez-Montero A. Sodium bicarbonate therapy in patients with metabolic acidosis. ScientificWorldJournal. 2014;2014:627673.
KDIGO 2012. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1).
Wesson DE, Jo C-H, Simoni J. Angiotensin II-mediated GFR decline in subtotal nephrectomy is due to acid retention associated with reduced GFR. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2015 May;30(5):762–70.
Wesson DE, Simoni J. Acid retention during kidney failure induces endothelin and aldosterone production which lead to progressive GFR decline, a situation ameliorated by alkali diet. Kidney Int. 2010 Dec;78(11):1128–35.
Goraya N, Wesson DE. Dietary interventions to improve outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens. 2015 Nov;24(6):505–10.
Wang XH, Mitch WE. Mechanisms of muscle wasting in chronic kidney disease. Nat Rev Nephrol. 2014;10(9):504– 16.
Zhang L, Rajan V, Lin E, Hu Z, Han HQ, Zhou X, et al. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J. 2011;25(5):1653.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
